bluebird bio (BLUE)
(Delayed Data from NSDQ)
$1.11 USD
+0.03 (2.78%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.11 USD
+0.03 (2.78%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
bluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nod
by Zacks Equity Research
bluebird (BLUE) and partner Bristol Myers clinch an FDA approval for their chimeric antigen receptor T cell immunotherapy Abecma to address relapsed or refractory multiple myeloma.
Bluebird (BLUE) Up 9.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD Study
by Zacks Equity Research
bluebird (BLUE) gains following the updated findings from the reported case of AML in LentiGlobin for SCD gene therapy program.
bluebird (BLUE) Moves 8.1% Higher: Will This Strength Last?
by Zacks Equity Research
Bluebird (BLUE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
bluebird (BLUE) Q4 Loss Narrower than Expected, Sales Miss
by Zacks Equity Research
bluebird (BLUE) reports a narrower-than-expected loss but misses sales estimates in the fourth quarter of 2020.
Biotech Stock Roundup: REGN's Drug Approval & Pipeline Updates From AMGN, BLUE
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Amgen (AMGN) and bluebird (BLUE).
bluebird (BLUE) Down on Suspension of Sickle Cell Disease Studies
by Zacks Equity Research
bluebird (BLUE) temporarily suspends two studies of LentiGlobin gene therapy in SCD because of reported Suspected Unexpected Serious Adverse Reactions of acute myeloid leukemia.
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for January 21st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Harpoon's (HARP) Multiple Myeloma Candidate Gets Orphan Drug Tag
by Zacks Equity Research
Harpoon (HARP) gets Orphan Drug designation by the FDA for HPN217 for the treatment of multiple myeloma.
Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY
by Zacks Equity Research
The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.
bluebird (BLUE) to Spin Off Oncology Unit Into Separate Entity
by Zacks Equity Research
bluebird (BLUE) to separate its severe genetic disease and oncology businesses into different and independent publicly traded companies. Shares up.
J&J (JNJ) Begins Rolling BLA Filing of Multiple Myeloma Drug
by Zacks Equity Research
J&J (JNJ) initiates the rolling submission of its BLA to the FDA for BCMA CAR-T therapy, ciltacabtagene autoleucel to treat adults with relapsed/refractory multiple myeloma.
Bluebird (BLUE) Down 3.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 4.23% and -25.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Sorrento (SRNE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sorrento (SRNE) will provide updates on earnings and revenues when its releases third-quarter 2020 results.
Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.
Will Bluebird Bio (BLUE) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlycoMimetics' Rivipansel Gets Rare Pediatric Disease Status
by Zacks Equity Research
GlycoMimetics' (GLYC) rivipansel gets a Rare Pediatric Disease designation by the FDA for the treatment of SCD in patients 18 years old and younger.
bluebird's MAA for Elivaldogene Autotemcel Accepted by EMA
by Zacks Equity Research
bluebird's (BLUE) MAA for elivaldogene autotemcel gene therapy for the treatment of patients with cerebral adrenoleukodystrophy is accepted by the the European Medicines Agency.
bluebird-Bristol Myers' CAR T Cell Therapy BLA Accepted by FDA
by Zacks Equity Research
The FDA accepts bluebird (BLUE) and Bristol Myers Squibb's BLA for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma.
Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Bluebird (BLUE) Down 7.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 81.15% and 95.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?